Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 356432, 11 pages
http://dx.doi.org/10.1155/2014/356432
Research Article

ATP Synthase β-Chain Overexpression in SR-BI Knockout Mice Increases HDL Uptake and Reduces Plasma HDL Level

1Department of Endocrinology, Shanghai Tenth People’s Hospital, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China
2Institute of Cardiovascular Science, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center, Beijing 100191, China
3Nanjing Medical University, Nanjing 210029, China

Received 11 January 2014; Revised 3 June 2014; Accepted 7 June 2014; Published 10 July 2014

Academic Editor: Giuseppina T. Russo

Copyright © 2014 Kexiu Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Gordon, J. L. Probstfield, R. J. Garrison et al., “High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies,” Circulation, vol. 79, no. 1, pp. 8–15, 1989. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. Brewer Jr., A. T. Remaley, E. B. Neufeld, F. Basso, and C. Joyce, “Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1755–1760, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Assmann and A. M. Gotto Jr., “HDL cholesterol and protective factors in atherosclerosis,” Circulation, vol. 109, no. 23, supplement 1, pp. III8–III14, 2004. View at Google Scholar · View at Scopus
  4. J. E. Feig, R. Shamir, and E. A. Fisher, “Atheroprotective effects of HDL: beyond reverse cholesterol transport,” Current Drug Targets, vol. 9, no. 3, pp. 196–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. V. Eckardstein, “HDL and arteriosclerosis: beyond reverse cholesterol transport,” Atherosclerosis, vol. 161, no. 1, pp. 1–16, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Gordon, J. Knoke, J. L. Probstfield, R. Superko, and H. A. Tyroler, “High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial,” Circulation, vol. 74, no. 6, pp. 1217–1225, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. S. E. Nissen, T. Tsunoda, E. M. Tuzcu et al., “Effect of recombinant ApoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2292–2300, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Getz, G. D. Wool, and C. A. Reardon, “HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders,” Current Pharmaceutical Design, vol. 16, no. 28, pp. 3173–3184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. Ansell, M. Navab, S. Hama et al., “Inflammatory/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment,” Circulation, vol. 108, no. 22, pp. 2751–2756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. N. E. Miller, A. La Ville, and D. Crook, “Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit,” Nature, vol. 314, no. 6006, pp. 109–111, 1985. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Acton, A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger, “Identification of scavenger receptor SR-BI as high density lipoprotein receptor,” Science, vol. 271, no. 5248, pp. 518–520, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Wang, T. Arai, Y. Ji, F. Rinninger, and A. R. Tall, “Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32920–32926, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. K. F. Kozarsky, M. H. Donahee, A. Rigotti, S. N. Iqbal, E. R. Edelman, and M. Krieger, “Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels,” Nature, vol. 387, no. 6631, pp. 414–417, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. K. F. Kozarsky, M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader, “Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 721–727, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Arai, N. Wang, M. Bezouevski, C. Welch, and A. R. Tall, “Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene,” The Journal of Biological Chemistry, vol. 274, no. 4, pp. 2366–2371, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Ueda, E. Gong, L. Royer, P. N. Cooper, O. L. Francone, and E. M. Rubin, “Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics,” The Journal of Biological Chemistry, vol. 275, no. 27, pp. 20368–20373, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. M. van Eck, J. Twisk, M. Hoekstra et al., “Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23699–23705, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Braun, B. L. Trigatti, M. J. Post et al., “Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice,” Circulation Research, vol. 90, no. 3, pp. 270–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. B. L. Trigatti, “Hepatic high-density lipoprotein receptors: roles in lipoprotein metabolism and potential for therapeutic modulation,” Current Atherosclerosis Reports, vol. 7, no. 5, pp. 344–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Rigotti, H. E. Miettinen, and M. Krieger, “The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues,” Endocrine Reviews, vol. 24, no. 3, pp. 357–387, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. L. O. Martinez, S. Jacquet, J. Esteve et al., “Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis,” Nature, vol. 421, no. 6918, pp. 75–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. P. D. Boyer, “The ATP synthase—a splendid molecular machine,” Annual Review of Biochemistry, vol. 66, pp. 717–749, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Wittig and H. Schägger, “Structural organization of mitochondrial ATP synthase,” Biochimica et Biophysica Acta, vol. 1777, no. 7-8, pp. 592–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. L. Moser, D. J. Kenan, T. A. Ashley et al., “Endothelial cell surface F1-Fo ATP synthase is active in ATP synthesis and is inhibited by angiostatin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6656–6661, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Scotet, L. O. Martinez, E. Grant et al., “Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I,” Immunity, vol. 22, no. 1, pp. 71–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Das, M. O. H. Mondragon, M. Sadeghian, V. B. Hatcher, and A. J. Norin, “A novel ligand in lymphocyte-mediated cytotoxicity: expression of the β subunit of H+ transporting ATP synthase on the surface of tumor cell lines,” The Journal of Experimental Medicine, vol. 180, no. 1, pp. 273–281, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Y. Chang, S. G. Park, S. Kim, and C. Kang, “Interaction of the C-terminal domain of p43 and the α subunit of ATP synthase: its functional implication in endothelial cell proliferation,” Journal of Biological Chemistry, vol. 277, no. 10, pp. 8388–8394, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Jacquet, C. Malaval, L. O. Martinez et al., “The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis,” Cellular and Molecular Life Sciences, vol. 62, no. 21, pp. 2508–2515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Zhang, V. S. Kamanna, M. C. Zhang, and M. L. Kashyap, “Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL,” Journal of Lipid Research, vol. 49, no. 6, pp. 1195–1201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. L. Chi and S. V. Pizzo, “Cell surface F1Fo ATP synthase: a new paradigm?” Annals of Medicine, vol. 38, no. 6, pp. 429–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Cavelier, P. M. Ohnsorg, L. Rohrer, and A. von Eckardstein, “The β-chain of cell surface F0F1 ATPase modulates ApoA-I and HDL transcytosis through aortic endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 1, pp. 131–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Rohrer, P. M. Ohnsorg, M. Lehner, F. Landolt, F. Rinninger, and A. von Eckardstein, “High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1,” Circulation Research, vol. 104, no. 10, pp. 1142–1150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. M. Ohnsorg, L. Rohrer, D. Perisa et al., “Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells,” Journal of Biological Chemistry, vol. 286, no. 10, pp. 7744–7754, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Trigatti, H. Rayburn, M. Viñals et al., “Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9322–9327, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Rigotti, B. L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger, “A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 23, pp. 12610–12615, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Malaval, M. Laffargue, R. Barbaras et al., “RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes,” Cellular Signalling, vol. 21, no. 1, pp. 120–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Marcil, A. Brooks-Wilson, S. M. Clee et al., “Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux,” The Lancet, vol. 354, no. 9187, pp. 1341–1346, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, “ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9774–9779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. M. A. Kennedy, G. C. Barrera, K. Nakamura et al., “ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation,” Cell Metabolism, vol. 1, no. 2, pp. 121–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. V. I. Zannis, A. Chroni, and M. Krieger, “Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL,” Journal of Molecular Medicine, vol. 84, no. 4, pp. 276–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. K. F. Kozarsky, K. Jooss, M. Donahee, and J. M. Wilson, “Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene,” Nature Genetics, vol. 13, pp. 54–62, 1996. View at Google Scholar · View at Scopus
  42. T. G. Redgrave, D. C. K. Roberts, C. E. West et al., “Separation of plasma lipoproteins by density-gradient ultracentrifugation,” Analytical Biochemistry, vol. 65, no. 1-2, pp. 42–49, 1975. View at Publisher · View at Google Scholar · View at Scopus
  43. R. E. Pitas, T. L. Innerarity, J. N. Weinstein, and R. W. Mahley, “Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy,” Arteriosclerosis, vol. 1, no. 3, pp. 177–185, 1981. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Schouten, M. Kleinherenbrink-Stins, A. Brouwer, D. L. Knook, and T. J. C. van Berkel, “Interaction in vivo and in vitro of apolipoprotein E-free high-density lipoprotein with parenchymal, endothelial and Kupffer cells from rat liver,” Biochemical Journal, vol. 256, no. 2, pp. 615–621, 1988. View at Google Scholar · View at Scopus
  45. S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong, “Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice,” Journal of Lipid Research, vol. 48, no. 7, pp. 1476–1487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Zhang, V. S. Kamanna, M. C. Zhang, and M. L. Kashyap, “Niacin inhibits surface expression of ATP synthase b chain in HepG2 cells: implications for raising HDL,” Journal of Lipid Research, vol. 49, no. 6, pp. 1195–1201, 2008. View at Publisher · View at Google Scholar · View at Scopus